Immunohistochemistry‐Based Consensus Molecular Subtypes as a Prognostic and Predictive Biomarker for Adjuvant Chemotherapy in Patients with Stage II Colorectal Cancer

BACKGROUND: For stage II colorectal cancer (CRC), the efficacy of adjuvant chemotherapy remains controversial. Consensus molecular subtype (CMS) has been validated to be a prognostic tool for CRCs. In this study, CMS status was investigated as a prognostic biomarker for the efficacy of adjuvant chem...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yaqi, Yao, Qianlan, Zhang, Long, Mo, Shaobo, Cai, Sanjun, Huang, Dan, Peng, Junjie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Gastrointestinal Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8186407/
https://www.ncbi.nlm.nih.gov/pubmed/32926498
http://dx.doi.org/10.1002/ONCO.13521

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8186407/
https://www.ncbi.nlm.nih.gov/pubmed/32926498
http://dx.doi.org/10.1002/ONCO.13521

Ejemplares similares